- Home
- RVYL vs NLSP Comparison
RVYL vs NLSP Comparison
Compare RVYL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- NLSP
- Stock Information
- Founded
- RVYL 2007
- NLSP 2015
- Country
- RVYL United States
- NLSP Switzerland
- Employees
- RVYL N/A
- NLSP N/A
- Industry
- RVYL Professional Services
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- NLSP Health Care
- Exchange
- RVYL Nasdaq
- NLSP Nasdaq
- Market Cap
- RVYL 13.3M
- NLSP 243.8M
- IPO Year
- RVYL N/A
- NLSP 2021
- Fundamental
- Price
- RVYL $2.06
- NLSP $4.96
- Analyst Decision
- RVYL Hold
- NLSP
- Analyst Count
- RVYL 1
- NLSP 0
- Target Price
- RVYL N/A
- NLSP N/A
- AVG Volume (30 Days)
- RVYL 94.9K
- NLSP 34.6K
- Earning Date
- RVYL 11-11-2024
- NLSP 11-01-2024
- Dividend Yield
- RVYL N/A
- NLSP N/A
- EPS Growth
- RVYL N/A
- NLSP N/A
- EPS
- RVYL N/A
- NLSP N/A
- Revenue
- RVYL $68,403,000.00
- NLSP N/A
- Revenue This Year
- RVYL N/A
- NLSP N/A
- Revenue Next Year
- RVYL $46.18
- NLSP N/A
- P/E Ratio
- RVYL N/A
- NLSP N/A
- Revenue Growth
- RVYL 42.88
- NLSP N/A
- 52 Week Low
- RVYL $0.89
- NLSP $4.08
- 52 Week High
- RVYL $5.48
- NLSP $29.68
- Technical
- Relative Strength Index (RSI)
- RVYL 62.76
- NLSP 46.37
- Support Level
- RVYL $1.91
- NLSP $4.52
- Resistance Level
- RVYL $2.30
- NLSP $5.64
- Average True Range (ATR)
- RVYL 0.26
- NLSP 0.48
- MACD
- RVYL 0.06
- NLSP 0.07
- Stochastic Oscillator
- RVYL 71.84
- NLSP 55.44
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.